More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$16.73B
EPS
6.75
P/E ratio
20.8
Price to sales
4.29
Dividend yield
--
Beta
0.362101
Previous close
$167.40
Today's open
$168.39
Day's range
$164.81 - $168.62
52 week range
$122.14 - $186.12
show more
CEO
Kyle W. Gano
Employees
2000
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
101218643
Issue type
Common Stock
Healthcare
Pharmaceuticals
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 11 hours ago

Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research • Nov 16, 2026

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London at 3:30 p.m. Greenwich Mean Time (10:30 a.m.
PRNewsWire • Nov 10, 2026

NBIX or GRDN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • Nov 10, 2026

Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 9, 2026

All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Nov 9, 2026

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research • Nov 9, 2026

NBIX vs. GRDN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Neurocrine Biosciences (NBIX) or Guardian Pharmacy Services (GRDN). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research • Nov 9, 2026

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from 5.6 to 2.0 A separate post-hoc analysis of KINECT-PRO™ data showed patient-reported improvement with INGREZZA across all six physical and socio-emotional areas assessed by the Tardive Dyskinesia Impact Scale (TDIS™) among participants reporting impacts to those areas at baseline SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey showing that adults with tardive dyskinesia (TD) reported fewer disruptions to work and school after starting treatment with INGREZZA® (valbenazine) capsules.1 A separate post-hoc analysis of the KINECT-PRO™ Phase 4 open-label study showed robust patient-reported improvement with INGREZZA across all six physical and socio-emotional areas measured by the Tardive Dyskinesia Impact Scale (TDIS™) among participants who reported impacts in those areas at baseline. The TDIS is the only psychometrically validated tool that measures the burden of TD from a patient's perspective.
PRNewsWire • Nov 5, 2026

Neurocrine Biosciences: Breaking Down A Solid Quarter
Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17% year-over-year sales growth to $801 million on strong volume gains. The Soleno Therapeutics acquisition and VYKAT XR approval expand NBIX's rare disease portfolio, with VYKAT XR showing strong initial adoption.
Seeking Alpha • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Neurocrine Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.